Information
Cette décision n'est disponible qu'en Anglais.
T 2091/21 (Industrial scalable lentiviral vector/GENETHON) 29-04-2022
Téléchargement et informations complémentaires:
SCALABLE LENTIVIRAL VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS
Oxford BioMedica (UK) Limited
GlaxoSmithKline Intellectual Property
Development Limited
Miltenyi Biotec GmbH
Ricker, Mathias
Strawman Limited
Hoffmann Eitle
James Poole Limited
Patentanwälte Isenbruck Bösl Hörschler PartG mbB
Summary of Facts and Submissions
I. The appeal is directed against the decision of an opposition division posted on 14 September 2021 to revoke the European patent 2 782 997 with the title "Scalable lentiviral vector production system compatible with industrial pharmaceutical applications".
II. The patent proprietor (hereinafter "the appellant") filed a notice of appeal on 24 November 2021 and paid the appeal fee on the same day.
III. By communication of 14 February 2022, the board informed the appellant that apparently no written statement of grounds of appeal had been filed, and that it was therefore to be expected that the appeal would be rejected as inadmissible. The appellant was informed that any observations had to be filed within two months of notification of the communication.
IV. No reply was received.
Reasons for the Decision
1. No written statement setting out the grounds of appeal was filed within the time limit provided by Article 108, third sentence, EPC in conjunction with Rules 99(2) and 126(2) EPC.
2. Therefore, the appeal has to be rejected as inadmissible (Rule 101(1) EPC).
Order
For these reasons it is decided that:
The appeal is rejected as inadmissible.